Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: Anti-LRP/LR-specific antibody IgG1-iS18 impedes adhesion and invasion of pancreatic cancer and neuroblastoma cells

Fig. 6

IgG1-iS18 reduces the invasive potential of AsPC-1 and IMR-32 cells through the ECM-like Matrigel™. Absorbance was measured at 620 nm after an incubation of 24 h and after staining with toluidine blue. CAT was used as a negative control. When treated with IgG1-iS18, the invasive potential of the AsPC-1 and IMR-32 cells was significantly decreased, respectively. The MCF-7 untreated value was set to 100%. The error bars represent standard deviation and p-values *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, Non-significant (N.S): p > 0.05

Back to article page